Ceva Santé Animale S.A.
Ceva
Ceva Santé Animale is one of the world's fastest-growing independent animal health companies, distinguished by its employee-and-PE consortium ownership structure and extraordinary manufacturing footprint. Founded in 1999 and headquartered in Libourne, France, Ceva generated approximately EUR 1.77 billion (~USD 1.9 billion) in 2024 revenue, employing 7,000 employees across 32 production sites and 21 R&D centers. Ceva's defining strength is its 12.8% capital expenditure-to-sales ratio—far above industry average—directing massive investment into vaccine fermentation, proprietary pheromone extraction, and in-ovo injection device manufacturing, with its landmark Monor, Hungary facility alone producing over 8 billion vaccine doses annually.
Strengths:
• Manufacturing Scale & Intensity: 32 owned production sites across 110+ countries—one of the industry's most extensive self-owned manufacturing networks—with 12.8% of revenue reinvested in capex
• Pheromone Niche Dominance: Proprietary Feliway and Adaptil pheromone products command near-monopoly positions in the global pet behavioral health market
• Vaccine Production Leadership: 54% of R&D budget allocated to vaccine development; Monor, Hungary facility produces 8+ billion doses annually of multi-component inactivated vaccines
• Strategic Gene Therapy Entry: 2025 acquisition of Scout Bio marks entry into companion animal gene therapy, positioning Ceva at the frontier of veterinary biotechnology
• Prestigious Shareholder Consortium: Backed by Temasek, Mérieux Institute, and ARCHIMED—providing virtually unlimited acquisition capital for strategic expansion
Weaknesses:
• Revenue Scale Gap: At ~$1.9B, Ceva remains significantly smaller than the Big Four (Zoetis, Merck, Boehringer, Elanco), limiting absolute R&D spend despite high percentage allocation
• Historical Livestock Concentration: Traditional strength in poultry and swine vaccines means the companion animal portfolio is still building depth relative to pure-play competitors
• Private Ownership Opacity: Limited public financial disclosure makes independent assessment of segment-level profitability and capacity utilization challengingRead MoreShow Less
Strengths:
• Manufacturing Scale & Intensity: 32 owned production sites across 110+ countries—one of the industry's most extensive self-owned manufacturing networks—with 12.8% of revenue reinvested in capex
• Pheromone Niche Dominance: Proprietary Feliway and Adaptil pheromone products command near-monopoly positions in the global pet behavioral health market
• Vaccine Production Leadership: 54% of R&D budget allocated to vaccine development; Monor, Hungary facility produces 8+ billion doses annually of multi-component inactivated vaccines
• Strategic Gene Therapy Entry: 2025 acquisition of Scout Bio marks entry into companion animal gene therapy, positioning Ceva at the frontier of veterinary biotechnology
• Prestigious Shareholder Consortium: Backed by Temasek, Mérieux Institute, and ARCHIMED—providing virtually unlimited acquisition capital for strategic expansion
Weaknesses:
• Revenue Scale Gap: At ~$1.9B, Ceva remains significantly smaller than the Big Four (Zoetis, Merck, Boehringer, Elanco), limiting absolute R&D spend despite high percentage allocation
• Historical Livestock Concentration: Traditional strength in poultry and swine vaccines means the companion animal portfolio is still building depth relative to pure-play competitors
• Private Ownership Opacity: Limited public financial disclosure makes independent assessment of segment-level profitability and capacity utilization challenging
In the press
All coverage →5 latest headlines3- Ceva Animal Health acquires AQUILÓN strengthening its leaderdhip in swine intestinal health - 3tres3.comwww.3tres3.com2026-06-10
- Ceva Animal Health to Host "Advancing Swine Health" Pre-Symposium at ESPHM 2026 - 3TRES3www.3tres3.com2026-06-08
- Clifford Chance acts on Japanese animal health JV Ceva Bussan - Law.asialaw.asia2026-06-02
- Clifford Chance advises Mitsui on creation of Ceva Bussan Animal Health joint venture - ETLegalWorld.comlegal.economictimes.indiatimes.com2026-06-01
- The long-term partnership behind Ceva Santé Animale’s global expansion - Temasekwww.temasek.com.sg2026-05-25
Ceva allocates 12.8% of annual sales to capital expenditure—substantially above industry average—directing funds into advanced vaccine fermentation, pheromone extraction, and in-ovo injection device manufacturing. Its landmark facility in Monor, Hungary 7,000 m² was purpose-built for multi-component inactivated vaccine mass production, with annual capacity exceeding 8 billion doses. Ceva acquired Scout Bio in 2025, entering the companion animal gene therapy space.
• Pet Behavioral Health: Feliway / Adaptil pheromone products
• Vaccines: Feligen / Vanguard partnership products
• Anti-infectives & Parasiticides
• Reproduction & AI technologies
• Poultry and swine vaccines traditional strength
Quick Facts
Headquarters
Libourne, Nouvelle-Aquitaine, France
Founded
1999
Employees
7,000
Revenue
EUR$1.8 B (~USD$1.9 B, 2024)
Factories
32 production sites globally
Presence
Operations in 110+ countries, direct offices in 47 countries
Listing
Private (employee + PE consortium)
Categories
9 categories · scroll for more
Related
Similar listed companies
- Eli Lilly and Company· $1.1 T
- Johnson & Johnson (J&J)· $616 B
- Allergan Aesthetics· $504 B
- AbbVie Inc.· $504 B
- F. Hoffmann-La Roche AG· $372 B
- Merck Animal Health· $360 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website , Ceva Official Website
Wikipedia — Ceva Santé Animale
Fitch Ratings — Ceva